# A Study in Asthmatics to Determine the Efficacy and Dose Response of Repeat Doses of GW870086X on Forced Expiratory Volume in 1 Second (FEV1)

> **NCT01245426** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 136 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** GW870086 2mg
- **DRUG:** GW870086 4mg
- **DRUG:** GW870086 Placebo
- **DRUG:** GW870086 1mg
- **DRUG:** GW870086 3mg

## Key facts

- **NCT ID:** NCT01245426
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2011-07
- **Final completion:** 2011-08
- **Target enrollment:** 136 (ACTUAL)
- **Last updated:** 2016-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01245426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01245426, "A Study in Asthmatics to Determine the Efficacy and Dose Response of Repeat Doses of GW870086X on Forced Expiratory Volume in 1 Second (FEV1)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01245426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*